Hypothesis: silver nanoparticles as an adjuvant for cancertherapy
- PMID: 24312783
- PMCID: PMC3846012
- DOI: 10.5681/apb.2012.020
Hypothesis: silver nanoparticles as an adjuvant for cancertherapy
Abstract
Cytotoxic agents are a main part of therapeutic process against the observed tumors, which lead to some unwished damages, due to drug uptake by normal body cells causing various tissue/organ failures associated with formal administration manners. But nowadays the risk is reduced by new target therapy techniques, of which the observed physical nature of micelles and nanosilver particles, governing their special behavior, could help using micelle-coated silver nanoparticles as a novel adjuvant for cancer target therapy.
Keywords: Cancertherapy; Micelle; Nanosilver.
References
-
- Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. Toxicology Letters. 2008;176:1–12. - PubMed
-
- Alt V, Bechert T, Steinrucke P, Wagener M, Seidel P, Dingeldein E, Domann E, Schnettler R. An in vitro assessment of the antibacterial properties and cytotoxicity of nanoparticulate silver bone cement. Biomaterials. 2004;25:4383–4391. - PubMed
-
- Bae Y, Jang WD, Nishiyama N, Fukushima S, Kataoka K. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and ph-triggered drug releasing properties for active intracellular drug delivery. Mol Biosyst. 2005;1:242–250. - PubMed
LinkOut - more resources
Full Text Sources